Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs

Abstract Background Day‐to‐day variability impacts safety of insulin therapy and the choice of monitoring strategies. Side‐by‐side comparisons of insulin formulations in diabetic dogs are scarce. Hypothesis/Objectives Insulin glargine 300 U/mL (IGla300) and insulin degludec (IDeg) are associated wit...

Full description

Bibliographic Details
Main Authors: Michelle Miller, Jully Pires, Katti Crakes, Rachel Greathouse, Nina Quach, Chen Gilor
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Journal of Veterinary Internal Medicine
Subjects:
Online Access:https://doi.org/10.1111/jvim.16178
id doaj-8ff011e4659c49f58812321a4c63cd80
record_format Article
spelling doaj-8ff011e4659c49f58812321a4c63cd802021-09-28T15:49:30ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762021-09-013552131213910.1111/jvim.16178Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogsMichelle Miller0Jully Pires1Katti Crakes2Rachel Greathouse3Nina Quach4Chen Gilor5Department of Veterinary Medicine and Epidemiology School of Veterinary Medicine, University of California Davis California USADepartment of Veterinary Medicine and Epidemiology School of Veterinary Medicine, University of California Davis California USADepartment of Veterinary Medicine and Epidemiology School of Veterinary Medicine, University of California Davis California USADepartment of Veterinary Medicine and Epidemiology School of Veterinary Medicine, University of California Davis California USADepartment of Veterinary Medicine and Epidemiology School of Veterinary Medicine, University of California Davis California USADepartment of Veterinary Medicine and Epidemiology School of Veterinary Medicine, University of California Davis California USAAbstract Background Day‐to‐day variability impacts safety of insulin therapy and the choice of monitoring strategies. Side‐by‐side comparisons of insulin formulations in diabetic dogs are scarce. Hypothesis/Objectives Insulin glargine 300 U/mL (IGla300) and insulin degludec (IDeg) are associated with less day‐to‐day glucose variability compared to porcine lente (PL) in diabetic dogs. Animals Seven intact male purpose‐bred beagles with toxin‐induced diabetes. Methods In this repeated measured study, PL, IGla300 and IDeg were compared in 2 phases: once‐daily (q24h) and twice‐daily (q12h) administration. Interstitial glucose concentrations (IG) were measured continuously throughout the study. For each formulation, maximal q24h dose was determined using the same algorithm (while avoiding hypoglycemia) and then maintained for 72 hours. In phase 2, 70% of the maximal q24h dose was administered q12h and maintained for 5 days regardless of hypoglycemia. Coefficient of variation (CV) and glycemic variability percentage (GVP) were calculated to determine day‐to‐day and intraday variability, respectively. Results There was no difference in day‐to‐day variability between PL, IGla300, and IDeg in the q24h phase. In the q12h phase, day‐to‐day variability was higher (P = .01) for PL (CV = 42.6 ± 6.8%) compared to IGla300 and IDeg (CV = 30.1 ± 7.7%, 25.2 ± 7.0%, respectively). The GVP of PL was lower (P = .02) compared to IGla300. There was no difference between PL, IGla300 and IDeg in %time IG < 70 mg/dL. Conclusions and Clinical Importance Insulin degludec and IGla300 administered q12h were associated with lower day‐to‐day variability, which might be advantageous in minimizing monitoring requirements without increasing the risk of hypoglycemia.https://doi.org/10.1111/jvim.16178basal insulindiabetes mellitusglycemic variabilityhypoglycemia
collection DOAJ
language English
format Article
sources DOAJ
author Michelle Miller
Jully Pires
Katti Crakes
Rachel Greathouse
Nina Quach
Chen Gilor
spellingShingle Michelle Miller
Jully Pires
Katti Crakes
Rachel Greathouse
Nina Quach
Chen Gilor
Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
Journal of Veterinary Internal Medicine
basal insulin
diabetes mellitus
glycemic variability
hypoglycemia
author_facet Michelle Miller
Jully Pires
Katti Crakes
Rachel Greathouse
Nina Quach
Chen Gilor
author_sort Michelle Miller
title Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
title_short Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
title_full Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
title_fullStr Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
title_full_unstemmed Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
title_sort day‐to‐day variability of porcine lente, insulin glargine 300 u/ml and insulin degludec in diabetic dogs
publisher Wiley
series Journal of Veterinary Internal Medicine
issn 0891-6640
1939-1676
publishDate 2021-09-01
description Abstract Background Day‐to‐day variability impacts safety of insulin therapy and the choice of monitoring strategies. Side‐by‐side comparisons of insulin formulations in diabetic dogs are scarce. Hypothesis/Objectives Insulin glargine 300 U/mL (IGla300) and insulin degludec (IDeg) are associated with less day‐to‐day glucose variability compared to porcine lente (PL) in diabetic dogs. Animals Seven intact male purpose‐bred beagles with toxin‐induced diabetes. Methods In this repeated measured study, PL, IGla300 and IDeg were compared in 2 phases: once‐daily (q24h) and twice‐daily (q12h) administration. Interstitial glucose concentrations (IG) were measured continuously throughout the study. For each formulation, maximal q24h dose was determined using the same algorithm (while avoiding hypoglycemia) and then maintained for 72 hours. In phase 2, 70% of the maximal q24h dose was administered q12h and maintained for 5 days regardless of hypoglycemia. Coefficient of variation (CV) and glycemic variability percentage (GVP) were calculated to determine day‐to‐day and intraday variability, respectively. Results There was no difference in day‐to‐day variability between PL, IGla300, and IDeg in the q24h phase. In the q12h phase, day‐to‐day variability was higher (P = .01) for PL (CV = 42.6 ± 6.8%) compared to IGla300 and IDeg (CV = 30.1 ± 7.7%, 25.2 ± 7.0%, respectively). The GVP of PL was lower (P = .02) compared to IGla300. There was no difference between PL, IGla300 and IDeg in %time IG < 70 mg/dL. Conclusions and Clinical Importance Insulin degludec and IGla300 administered q12h were associated with lower day‐to‐day variability, which might be advantageous in minimizing monitoring requirements without increasing the risk of hypoglycemia.
topic basal insulin
diabetes mellitus
glycemic variability
hypoglycemia
url https://doi.org/10.1111/jvim.16178
work_keys_str_mv AT michellemiller daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs
AT jullypires daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs
AT katticrakes daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs
AT rachelgreathouse daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs
AT ninaquach daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs
AT chengilor daytodayvariabilityofporcinelenteinsulinglargine300umlandinsulindegludecindiabeticdogs
_version_ 1716865499435892736